



## Nominate your trial for the "Trial of the Month"

The CCTC provides a platform to increase awareness of clinical trials within the COMET community. If you are interested in having your trial featured in our "Trial of the Month" feature, please email Ammar Bookwala (cometrials@smh.ca) by June 25, 2012.

## Have a question, comment or concern?

Please contact Ammar Bookwala, CCTC Project Manager at CometTrials@smh.ca or call at 416-809-3915

## Welcome to the CCTC Monthly Newsletter!

- The COMET Clinical Trials Consortium is a website dedicated to improving recruitment in oncology clinical trials in the Greater Toronto Area and surrounding regions
- In our newsletter, you shall find updates about membership, featured clinical trials and news about upcoming COMET events!

## Key Features of the CCTC

- Free patient referral website for medical oncologists and other cancer care specialists
- Database of actively recruiting oncology clinical trials
- Discussion Forum for best practices in cancer care
- LinkingHealthProfessionals email provided to all members to stay in touch with the COMET community
- GPS system that matches patients with the closest clinical trial site to their home address

## Membership Update

The COMET Clinical Trials Consortium currently has 129 members at 19 Oncology sites. There are currently 64 active trials on the website. Please view the chart below for a detailed breakdown of members and trials per site as of May 31, 2012:

Institution	Number of Members	Number of Active Clinical Trials
Cancer Center of Southeastern Ontario	1	0
Credit Valley Hospital	13	7
Durham Regional Cancer Center	17	14
Grand River Hospital	14	5
Humber River Hospital	1	0
Markham Stouffville Hospital	1	0
Mount Sinai Hospital	1	0
North York General Hospital	7	1
Princess Margaret Hospital	16	21
Royal Victoria Hospital	7	6
Southlake Regional Health Center	8	1
St. Joseph's Healthcare Hamilton	2	0
St. Joseph's Health Center	3	2
St. Michael's Hospital	7	4
Sunnybrook/Odette Cancer Center	15	19
Toronto East General Hospital	6	1
Trillium Health Centre	5	3
Windsor Regional Hospital	2	0
York Central Hospital	3	0
<b>Total</b>	<b>129</b>	<b>84</b>

## Sponsors

Founding Sponsor



Hoffman-La Roche Limited

At Roche, our primary objective is to provide healthcare solutions that deliver superior options for diagnosis and treatment to clinicians and patients. As one of the world's leading healthcare companies with combined strength in pharmaceuticals and diagnostics, no company is better suited for this task.



Please help the CCTC increase membership by referring the website to fellow principal investigators, physicians and clinical research coordinators in oncology.

## Trial of the Month

**Name:** A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer

**Acronym:** CRC.6

**Primary Outcome:** This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.

Treatment Arms:	Arms	Assigned Interventions
	<b>Experimental: Arm I</b> Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46-48 hours (FOLFOX) on day 1. Patients also receive oral celecoxib once daily on days 1-14 beginning on day 1 of course 2. Courses repeat every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.	Drug: <b>Celecoxib</b> ( Given orally ) Drug: <b>Fluorouracil</b> ( Given IV ) Drug: <b>Leucovorin calcium</b> ( Given IV ) Drug: <b>Oxaliplatin</b> ( Given IV )
	<b>Placebo Comparator: Arm II</b> Patients receive FOLFOX as in arm I and oral placebo once daily on days 1-14 beginning on day 1 of course 2. Courses repeat every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.	Drug: <b>Fluorouracil</b> ( Given IV ) Drug: <b>Leucovorin calcium</b> ( Given IV ) Drug: <b>Oxaliplatin</b> ( Given IV ) Other: <b>Placebo</b> ( Given orally )
	<b>Experimental: Arm III</b> Patients receive FOLFOX and celecoxib as in arm I. Courses repeat every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.	Drug: <b>Celecoxib</b> ( Given orally ) Drug: <b>Fluorouracil</b> ( Given IV ) Drug: <b>Leucovorin calcium</b> ( Given IV ) Drug: <b>Oxaliplatin</b> ( Given IV )
	<b>Placebo Comparator: Arm IV</b> Patients receive FOLFOX and placebo as in arm II. Courses repeat every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.	Drug: <b>Leucovorin calcium</b> ( Given IV ) Drug: <b>Oxaliplatin</b> ( Given IV ) Other: <b>Placebo</b> ( Given orally )

### CCTC Study Location(s) in the Greater Toronto Area and Surrounding Regions:

Hospital	Principal Investigator	Clinical Research Coordinator
Durham Regional Cancer Center	Rama Koneru	Wanada Parsons
Royal Victoria Hospital	Rob El Maraghi	Kim Marsh Gray
St. Michael's Hospital	Christine Brezden-Masley	Susan Sullivan
Trillium Health Center	John Gapski	Kathryn Zurawel

## Thanks for Attending!

We would like to thank all CCTC members who attended our Clinical Research Coordinator and Site Administrator Training at Brassaii Restaurant on May 22, 2012. We had a great turnout from sites across the Greater Toronto Area, and appreciate all the feedback received about the website.

## Have a question, comment or concern?

Please contact Ammar Bookwala, CCTC Project Manager at CometTrials@smh.ca or call at 416-809-3915